Vascepa's Approval Status
Vascepa (icosapent ethyl) gained FDA approval in 2012 for severe hypertriglyceridemia and expanded in 2020 via the REDUCE-IT trial for cardiovascular risk reduction in high-risk patients. It's already fully approved and marketed by Amarin Corporation. No standard approval process exists to "speed up," as it's complete.[1]
Expanded Access or Compassionate Use
Patients unable to access Vascepa through normal channels (e.g., shortages) can request expanded access via Amarin or FDA's program for investigational uses. Submit Form FDA 3926 to FDA; approval takes ~30 days but isn't guaranteed and doesn't alter market approval.[2]
Off-Label or Urgent Need Requests
Physicians can petition FDA for off-label promotion or urgent single-patient IND if life-threatening. This bypasses full trials but requires strong evidence; processing is 30 days max under emergency rules. Contact Amarin's medical info line first.[3]
Generic or Biosimilar Acceleration
No generics yet due to patents (e.g., U.S. Patent 8,946,233 expires 2039). Challenges via ANDA Paragraph IV can trigger 180-day exclusivity for first filer, indirectly speeding market entry. Hikma and others filed suits; track at DrugPatentWatch.com.[4][5]
Pricing or Access Shortcuts
Use patient assistance programs like Amarin's CAREPATH for copay cards (up to $18/month) or free drug for uninsured. Medicare covers it post-2020 approval. These reduce barriers without changing approval timeline.[6]
[1]: FDA.gov - Vascepa Label
[2]: FDA.gov - Expanded Access
[3]: FDA.gov - Single-Patient IND
[4]: DrugPatentWatch.com - Vascepa Patents
[5]: FDA Orange Book - Vascepa
[6]: Amarin.com - Patient Support